title: Retinal Astrocytes respond to IL-17 differently than Retinal Pigment Epithelial cells.
abstract: IL-17+ T cells make up the majority of the infiltrating cells in the inflamed eye during the development of EAU. However, the role of IL-17 in ocular inflammation is poorly defined. Given that the primary target cells for IL-17 are parenchymal cells of the tissue, we investigated the in vitro effect of IL-17 on mouse RACs and RPE cells. Our results showed that although RACs and RPE cells expressed the IL-17R, RACs responded to IL-17 by producing increased amounts of proinflammatory cytokines and chemokines, leading to increased migration of granulocytes, whereas RPE cells responded to the same concentration of IL-17 by expressing increased levels of SOCS proteins, resulting in only limited production of proinflammatory cytokines and chemokines and an increased amount of suppressive cytokines, such as LIF. The combination of IL-17 and IFN-gamma had a synergistic effect on cell migration with RACs but an antagonistic effect with RPE. In addition, specific inhibitors of the PI3K/Akt signaling pathway completely blocked inflammatory cell migration induced by chemokines released by IL-17-stimulated RACs. Our results demonstrate that IL-17 can induce a pro- or anti-inflammatory effect in the eye, depending on the parenchymal cells stimulated.
authors.affiliation: Department of Ophthalmology and Visual Sciences, Kentucky Lions Eye Center, University of Louisville, Louisville, Kentucky 40202, USA.
authors.forename: Yan
authors.initials: Y
authors.lastname: Ke
authors.forename: Guomin
authors.initials: G
authors.lastname: Jiang
authors.forename: Deming
authors.initials: D
authors.lastname: Sun
authors.forename: Henry J
authors.initials: HJ
authors.lastname: Kaplan
authors.forename: Hui
authors.initials: H
authors.lastname: Shao
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000276:immunology / Q000494:pharmacology; D001253:Astrocytes / Q000166:cytology / Q000276:immunology*; D002465:Cell Movement / Q000187:drug effects / Q000276:immunology*; D018925:Chemokines / Q000276:immunology; D004847:Epithelial Cells / Q000166:cytology / Q000276:immunology*; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects / Q000276:immunology*; D007249:Inflammation / Q000276:immunology; D007371:Interferon-gamma / Q000276:immunology / Q000494:pharmacology; D020381:Interleukin-17 / Q000276:immunology* / Q000494:pharmacology; D051379:Mice; D009928:Organ Specificity / Q000187:drug effects / Q000276:immunology; D019869:Phosphatidylinositol 3-Kinases / Q000276:immunology; D051057:Proto-Oncogene Proteins c-akt / Q000276:immunology; D055213:Retinal Pigment Epithelium / Q000166:cytology / Q000276:immunology*; D015398:Signal Transduction / Q000187:drug effects / Q000276:immunology; D050826:Suppressor of Cytokine Signaling Proteins / Q000276:immunology
chemical_list: D000998:Antiviral Agents; D018925:Chemokines; D020381:Interleukin-17; D050826:Suppressor of Cytokine Signaling Proteins; D007371:Interferon-gamma; D019869:Phosphatidylinositol 3-Kinases; D051057:Proto-Oncogene Proteins c-akt
references.citation: Invest Ophthalmol Vis Sci. 2006 Apr;47(4):1543-9
references.pmid: 16565390
references.citation: Eur J Immunol. 1982 Feb;12(2):134-40
references.pmid: 6978817
references.citation: J Exp Med. 1996 Nov 1;184(5):1963-74
references.pmid: 8920883
references.citation: J Neuroimmunol. 2005 Nov;168(1-2):118-27
references.pmid: 16154209
references.citation: J Immunol. 2007 May 1;178(9):5578-87
references.pmid: 17442940
references.citation: Nat Immunol. 2003 Jun;4(6):540-5
references.pmid: 12754505
references.citation: Nature. 1997 Jun 26;387(6636):917-21
references.pmid: 9202125
references.citation: Invest Ophthalmol Vis Sci. 2008 Jan;49(1):282-9
references.pmid: 18172104
references.citation: Ann Rheum Dis. 2006 Nov;65 Suppl 3:iii29-33
references.pmid: 17038468
references.citation: Prog Retin Eye Res. 2008 Sep;27(5):527-35
references.pmid: 18723108
references.citation: J Immunol. 1998 Jul 1;161(1):409-14
references.pmid: 9647250
references.citation: Trends Immunol. 2003 Dec;24(12):659-66
references.pmid: 14644140
references.citation: Nat Rev Immunol. 2002 Jun;2(6):410-6
references.pmid: 12093007
references.citation: J Autoimmun. 2005 Feb;24(1):39-46
references.pmid: 15725575
references.citation: J Clin Invest. 1998 Jan 15;101(2):311-20
references.pmid: 9435302
references.citation: J Immunol. 2009 Mar 1;182(5):3183-90
references.pmid: 19234216
references.citation: Nat Med. 2007 Jun;13(6):711-8
references.pmid: 17496900
references.citation: J Leukoc Biol. 2002 Jan;71(1):1-8
references.pmid: 11781375
references.citation: Nat Immunol. 2003 Jun;4(6):546-50
references.pmid: 12754506
references.citation: Int Immunol. 2008 Feb;20(2):209-14
references.pmid: 18156624
references.citation: J Clin Invest. 2003 Feb;111(4):469-78
references.pmid: 12588885
references.citation: J Immunol. 2001 Jun 15;166(12):7082-9
references.pmid: 11390452
references.citation: Cell. 1999 Sep 3;98(5):597-608
references.pmid: 10490099
references.citation: J Immunol. 2001 Jun 15;166(12):7023-32
references.pmid: 11390446
references.citation: J Neuroimmunol. 2004 Jun;151(1-2):195-200
references.pmid: 15145618
references.citation: Invest Ophthalmol Vis Sci. 2008 Oct;49(10):4620-30
references.pmid: 18450597
references.citation: J Neuroimmunol. 2002 Feb;123(1-2):35-40
references.pmid: 11880147
references.citation: Cytokine. 2008 Sep;43(3):402-7
references.pmid: 18701318
references.citation: Immunity. 2008 Apr;28(4):454-67
references.pmid: 18400188
references.citation: J Immunol. 2002 Apr 15;168(8):3707-11
references.pmid: 11937520
references.citation: J Immunol. 1988 Mar 1;140(5):1506-10
references.pmid: 3126227
references.citation: Invest Ophthalmol Vis Sci. 2007 Sep;48(9):4153-61
references.pmid: 17724201
references.citation: Exp Eye Res. 2006 Feb;82(2):323-31
references.pmid: 16125173
references.citation: J Immunol. 1998 Apr 1;160(7):3513-21
references.pmid: 9531313
references.citation: Eur J Immunol. 2002 Mar;32(3):710-9
references.pmid: 11870615
references.citation: J Neuroimmunol. 2003 Nov;144(1-2):1-8
references.pmid: 14597092
references.citation: J Immunol. 2003 Nov 15;171(10):5624-30
references.pmid: 14607971
references.citation: Cell Immunol. 2005 Oct;237(2):123-30
references.pmid: 16386239